In a study by Chang et al., RA patients treated with Janus kinase inhibitors (JAKi), an immune modulating drug, exhibited a significant increase in serum levels of total HDL particle number, small-sized HDL particles, and HDL-related metabolites, including total lipids, phospholipids, cholesterol, cholesterol esters, and free cholesterol, concurrent with decreased disease activity and reduced CRP levels. Here, CRP is linked to rheumatoid arthritis.